The effectiveness of cannabidiol (CBD) in reducing anxiety among patients with advanced breast cancer has become an intriguing subject for researchers, especially in the context of scan-related anxiety. A recent study conducted by researchers from the Dana-Farber Cancer Institute and Mass General
Washington University School of Medicine in St. Louis (WashU Medicine) has been awarded a significant five-year, $10.8 million grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH). This funding renewal aims to advance the institution's ongoing research in
Rett syndrome is a severe neurological disorder primarily affecting young girls, leading to significant cognitive, motor, and communication impairments. The disorder is linked to mutations in the MeCP2 gene, which encodes the methyl-CpG binding protein 2 (MeCP2). Researchers have long sought to
A drug initially celebrated for its potential in treating a rare liver disease has come under scrutiny following alarming safety findings. Ocaliva, developed by Intercept Pharmaceuticals and now under Alfasigma's ownership, was initially viewed as a breakthrough treatment for primary biliary
The recent endorsement of Neuraxpharm's ublituximab (BRIUMVI®) by the National Institute for Health and Care Excellence (NICE) marks a significant step forward in the treatment of relapsing-remitting multiple sclerosis (RRMS). This approval is a notable accomplishment for the European
AbbVie's recent acquisition of Nimble Therapeutics, a Roche spinout specializing in peptide-based oral drugs for immune diseases, represents a strategic move to enhance its already robust immunology pipeline. The $200 million deal is aimed at bolstering AbbVie's portfolio, particularly
